Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients
The primary aim of this study is to determine whether we can identify human lung cancer tumor cells in the peripheral blood of lung cancer patients.
Checked against the public recordLast updated Jun 22, 2022 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Stanford University
- Interventions being studied
- Procedure: phlebotomy
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria:Inclusion Criteria:Inclusion Criteria (Cases): 1. Advanced stage (IIIB with malignant effusion or IV) histologically or cytologically confirmed NSCLC 2. Patients must be newly diagnosed (untreated) or have evidence of disease progression at the time of sample collection 3. ability to sign informed consent 4. at least 18 years of age Inclusion Criteria (Controls): 1. no known prior or active malignancy 2. ability to sign informed consent 3. at least 18 years of age Exclusion Criteria:1. history of any other cancer other than non-melanoma skin cancer within the last 5 years Exclusion Criteria:1. history of any other cancer other than non-melanoma skin cancer within the last 5 years 2\. pregnant women
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Stanford University School of MedicineStanford, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 22, 2022. Always confirm current availability with the study team.